Intranasal LMWH against COVID-19

ZonMW0 个研究点目标入组 34 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

none yet

•In order to be eligible for participation, a participant must:
•- be able to provide written informed consent (Verbal informed consent or deferred informed concent will be used for the initial screening visit, where written informed consent will be obtained).
•- be physically healthy (as defined by not suffering from any illness or disease obstructing general daily functioning)
•- be aged between 18 – 65 years
•- be sufficiently well versed in the Dutch language, subject to the opinion of the Investigator

•If any of the following apply to someone wishing to participate, he/she is rendered ineligible for participation, a participant:
•- is unlikely to comply with study procedures, as deemed by the recruiting research doctor/nurse
•- has mental disorders that in the view of the investigator would interfere with adherence to study procedures or might impair a decision to participate in the study
•- has a known allergy or intolerance to LWWH or heparine-related products, as well as a medical history of heparine inducted thrombocytopenia (HIT).
•- has any relevant clinical medical condition that is in the opinion of the investigator to make a volunteer unsuitable for participation in the study (under which underlying haematological disorders or bleeding disorder.
•- has (anamnestic) evidence of a respiratory infection in the 4 weeks prior to enrolment.
•- has a tympanic temperature exceeding 38,5 degrees Celsius during the screening and clinical visits.
•- has frequent nosebleeds (>1/ month).

发起方